Avenio AI has appointed Dr. Cyrus Ghobadi as a Board Advisor, coinciding with Artiko Pharma's adoption of Avenio's Intelligent Protocol Hub to streamline clinical development processes.
Dr. Ghobadi, a seasoned expert with extensive experience at major pharmaceutical companies, will leverage Avenio AI's technology to enhance protocol authoring and reduce timelines from IND submission to first-patient-in. His dual perspective as both a physician and a clinical developer positions him uniquely to address common bottlenecks in clinical trials, which often lead to costly delays and inefficiencies.
Artiko Pharma Consulting, founded by Dr. Ghobadi, aims to provide small and mid-sized biotech firms with high-level clinical strategy and execution. By implementing Avenio's Intelligent Protocol Hub, Artiko seeks to improve the quality and speed of clinical documentation, ensuring that processes are both rigorous and audit-ready.
This partnership highlights the growing importance of AI in clinical development, particularly in addressing the significant costs associated with protocol authoring and amendments. With Avenio AI's platform, companies can expect enhanced collaboration and risk management, ultimately leading to more efficient drug development cycles.